News

The FDA just approved ranibizumab (Lucentis) as an ocular implant to be injected into the eye for people with wet macular degeneration, based upon the successful Archway study run under the FDA umb...

EyePoint Pharmaceuticals recently announced results of the Phase 1 clinical trial of their new wet age-related macular degeneration treatment, EYP-1901.

The new device offers a continuous therapeutic dose of ranibizumab to the eye in place of regular eye injections.

Researchers compared the visual outcomes and rate of intraoperative complications in patients with nAMD and control eyes that did not have nAMD that underwent phacoemulsification cataract surgery o...

There are five eye diseases that are the leading causes of blindness and low vision in the United States: age-related macular degeneration, cataracts, glaucoma, diabetic retinopathy and eye injurie...

Researchers discovered that levodopa is safe, well-tolerated and not only improved visual outcomes but also delayed anti-VEGF injections.

Researchers from the New York Eye and Ear Infirmary of Mount Sinai announced results of a study that analyzed the speed and accuracy of a new artificial intelligence (AI) algorithm in detecting ag...

The new technology will be helpful in providing an earlier diagnosis of age-related macular degeneration.

Researchers found an increased risk for the development of ocular hypertension and glaucoma with frequent anti-VEGF injections over a 6-month period.